Condition: Metastatic Breast Cancer · Sponsor: Veru Inc.
STAGE 1: To determine the safety of enobosarm 9 milligram (mg) once daily (QD) used in combination with a CDK 4/6 inhibitor \[Verzenio® (abemaciclib) tablets, for oral use, 150 mg twice daily (BID)\]. STAGE 2: To demonstrate the efficacy and safety of enobosarm 9 mg QD in combination with abemaciclib 150 mg BID (Enobosarm Combination Group) versus Estrogen Blocking Agent (Control Treatment Group) in the treatment of estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-), androgen receptor positive (AR+) with a AR% nuclei staining ≥40% metastatic breast cancer that have previously experienced disease progression on an estrogen blocking agent plus (palbociclib) as measured by progression free survival (PFS) according to RECIST 1.1 criteria.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Ironwood Cancer & Research Centers | Chandler, Arizona, United States | — |
| Banner MDACC | Gilbert, Arizona, United States | — |
| Arizona Oncology Associates, PC-HOPE | Tucson, Arizona, United States | — |
| Los Angeles Cancer Network One Oncology | Los Angeles, California, United States | — |
| UCLA Parkside Cancer Center | Los Angeles, California, United States | — |
| Sharp Center for Research | San Diego, California, United States | — |
| Sansum Clinic, CA | Santa Barbara, California, United States | — |
| Innovative Clinical Research Institute | Whittier, California, United States | — |
| Med OncologyHematology Consultants, PA Newark | Newark, Delaware, United States | — |
| Lakes Research | Miami Lakes, Florida, United States | — |
| Maryland Oncology Hematology, P.A. | Annapolis, Maryland, United States | — |
| Baystate Regional Cancer Program - D'Amour Center for Cancer Care | Springfield, Massachusetts, United States | — |
+ 18 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05065411